Market research
PHH2.F Paul Hartmann AG
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 707M
- P/E ratio
- 11.55
- Analyst target
- Not available
- Dividend yield
- 4.0%
- Beta
- 0.48
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- DE0007474041
- Market cap
- 707M
- P/E ratio
- 11.55
- Analyst target
- Not available
- Dividend yield
- 4.0%
- Beta
- 0.48
About
About Paul Hartmann AG
Paul Hartmann AG manufactures and sells medical and care products in Germany, the rest of Europe, the Middle East, Africa, Asia and Pacific region, and the Americas. The company operates through three segments: Wound Care, Incontinence Management, and Infection Management. It offers absorbent underwear, incontinence pads and pants, and fixation pants; medical skincare products; wound management products, such as hydro active wound and silicone SAP dressings, post-op dressings, nature care, adhesive fixation, non-adhesive fixation, gauze, sponges/tamponades, contact layers, absorption pads, cotton, and negative pressure wound therapy; compression, universal, zinc paste, and padding bandages; and hands, skin, surface, instruments, and equipment disinfection and hygiene products. In addition, the company sells operating theater products, including surgical drapes, operating theater clothing, surgical gloves, surgical absorbents and instruments; various Mediset products; patient care products, such as hygiene and maternity products, examination gloves, and nursing care products; diagnostics, such as blood pressure monitors, scale, and thermometers; first aid products; and cotton wool and cosmetic products. It sells its products under the CombiSet, DermaPlast, MoliCare, Sterillium, Veroval, and Zetuvit brands. Paul Hartmann AG was founded in 1818 and is headquartered in Heidenheim, Germany.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PHH2.F discussion.
5 years, 4 months ago
Paul Hartmann AG is currently in a long term downtrend where the price is trading 1.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.6.
Paul Hartmann AG's total revenue sank by 0.0% to $560M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $12M since the same quarter in the previous year.
Finally, its free cash flow grew by 150.9% to $61M since the same quarter in the previous year.
Based on the above factors, Paul Hartmann AG gets an overall score of 2/5.